At Roche, we believe that accessible and reliable diagnostics are essential in tackling this global health challenge. As part of our commitment to advancing hepatitis care, we launched the Elecsys® HCV Duo assay in Indonesia. This advanced assay detects Hepatitis C by identifying both the HCV core antigen and antibodies, allowing for early diagnosis even before symptoms appear. Early detection is crucial as it helps prevent progression to chronic conditions and reduces the overall impact of hepatitis. Together, we can ensure that everyone has access to effective and timely testing. Speak to your healthcare provider about the importance of Hepatitis C testing because everyone deserves to get tested. #earlydetection #liverdisease #hepatitisawareness #HCV MC-ID-00537
Roche’s Post
More Relevant Posts
-
MannKind announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for Clofazimine Inhalation Suspension (MNKD-101), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease. This single registrational study – identified as ICoN-1 – anticipated getting underway by end of June 2024 in the U.S. and internationally in the second half of the year. Pulmonary NTM infection is recognized as a major global health concern due to its rising prevalence – particularly in the U.S. and Asia Pacific region. https://bit.ly/3Wio8lg #MNKD #NTM #NTMlungDisease
-
-
No doubt we are facing a deep shift in our research! Sanofi is pioneering the future of medicine with #MonoclonalAntibody (mAb), a key technology of our #Immunoscience ambition. 🔬 Our latest video highlights how mAb technology is creating breakthroughs in treating chronic inflammatory diseases and holds promise for preventing infectious diseases like bronchiolitis caused by Respiratory Syncytial Virus #RSV 🦠 Are you now a mAb expert? ✨
-
Our team was thrilled to host a panel discussion on the critical role of patient perspectives in Hepatitis B research at the 2024 International Hepatitis B Meeting in Chicago today! 🌟 The diverse panel of experts discussed perspectives across the Hepatitis B research community, focusing on how patient insights drive innovation, improve trial design and shape research priorities in the fight against Hepatitis B. We look forward to sharing diverse perspectives on how patients will shape the future of Hepatitis B research and ways to better collaborate with patients at every stage. Together, let's embrace a patient-guided approach to accelerate finding better treatments and a cure for Hepatitis B! #HepatitisB #HepB #PatientPerspectives #PatientFirst
-
-
Our team was thrilled to host a panel discussion on the critical role of patient perspectives in Hepatitis B research at the 2024 International Hepatitis B Meeting in Chicago today! 🌟 The diverse panel of experts discussed perspectives across the Hepatitis B research community, focusing on how patient insights drive innovation, improve trial design and shape research priorities in the fight against Hepatitis B. We look forward to sharing diverse perspectives on how patients will shape the future of Hepatitis B research and ways to better collaborate with patients at every stage. Together, let's embrace a patient-guided approach to accelerate finding better treatments and a cure for Hepatitis B! #HepatitisB #HepB #PatientPerspectives #PatientFirst
-
-
Our team was thrilled to host a panel discussion on the critical role of patient perspectives in Hepatitis B research at the 2024 International Hepatitis B Meeting in Chicago today! 🌟 The diverse panel of experts discussed perspectives across the Hepatitis B research community, focusing on how patient insights drive innovation, improve trial design and shape research priorities in the fight against Hepatitis B. We look forward to sharing diverse perspectives on how patients will shape the future of Hepatitis B research and ways to better collaborate with patients at every stage. Together, let's embrace a patient-guided approach to accelerate finding better treatments and a cure for Hepatitis B! #HepatitisB #HepB #PatientPerspectives #PatientFirst
-
-
Early/Late Phase and Regulatory Strategy, RWE & RWD, Market Access, Logistics at Parexel Biotech
Our team was thrilled to host a panel discussion on the critical role of patient perspectives in Hepatitis B research at the 2024 International Hepatitis B Meeting in Chicago today! 🌟 The diverse panel of experts discussed perspectives across the Hepatitis B research community, focusing on how patient insights drive innovation, improve trial design and shape research priorities in the fight against Hepatitis B. We look forward to sharing diverse perspectives on how patients will shape the future of Hepatitis B research and ways to better collaborate with patients at every stage. Together, let's embrace a patient-guided approach to accelerate finding better treatments and a cure for Hepatitis B! #HepatitisB #HepB #PatientPerspectives #PatientFirst
-
-
Our team was thrilled to host a panel discussion on the critical role of patient perspectives in Hepatitis B research at the 2024 International Hepatitis B Meeting in Chicago today! 🌟 The diverse panel of experts discussed perspectives across the Hepatitis B research community, focusing on how patient insights drive innovation, improve trial design and shape research priorities in the fight against Hepatitis B. We look forward to sharing diverse perspectives on how patients will shape the future of Hepatitis B research and ways to better collaborate with patients at every stage. Together, let's embrace a patient-guided approach to accelerate finding better treatments and a cure for Hepatitis B! #HepatitisB #HepB #PatientPerspectives #PatientFirst
-
-
Our team was thrilled to host a panel discussion on the critical role of patient perspectives in Hepatitis B research at the 2024 International Hepatitis B Meeting in Chicago today! 🌟 The diverse panel of experts discussed perspectives across the Hepatitis B research community, focusing on how patient insights drive innovation, improve trial design and shape research priorities in the fight against Hepatitis B. We look forward to sharing diverse perspectives on how patients will shape the future of Hepatitis B research and ways to better collaborate with patients at every stage. Together, let's embrace a patient-guided approach to accelerate finding better treatments and a cure for Hepatitis B! #HepatitisB #HepB #PatientPerspectives #PatientFirst
-
-
Ensure that people with Primary Immunodeficiency in South Africa receive optimal treatment and support
World PI Week 2024 - Our Stories Access to care for all PID patients, everywhere Let’s make early diagnosis & timely access to quality treatment a reality worldwide 💖 Zoe's Story 💖 6 KEY MESSAGES ON IMMUNOGLOBULIN THERAPIES Immunoglobulin replacement therapy, is the administration of life-saving immunoglobulin therapies derived from human plasma which are protective against a broad range of infections Immunoglobulin therapies are absolutely essential, lifelong treatments for the majority of people with primary immunodeficiency Read more on: https://lnkd.in/dUzuPQAQ Together, bringing about change for primary immunodeficiency patients in South Africa. Together, We Make a Difference. You are not alone www.pinsa.org.za #primaryimmunodeficiency #WorldPIWeek #iPopi #RareDiseasesSA #PiNSA #primaryimmunedisease #PIDs #ImmuneDeficiencyFoundation
-
Clinical Hematologist , Head of Thalassemia and Sickle Cell Unit,Head of the Expertise Center of Hemoglobin Diseases and Their Complications,Hippokrateio General Hospital
📌 Eliminating Hepatitis C: Transforming Lives Through teamwork and innovative treatments, we achieved the micro-elimination of Hepatitis C among patients with thalassemia. This success has significantly improved their quality of life by reducing liver complications . Our approach focused on close collaboration between hematologists and hepatologists, ensuring comprehensive screening, timely access to care, and effective therapies. The use of direct-acting antivirals (DAAs) delivered cure rates exceeding 90% across all fibrosis stages, proving that elimination of this virus is not just a goal—it’s a reality . This project is a testament to the power of organization, innovation, and commitment to patient care. As we move toward the global 🌍 elimination of Hepatitis C by 2030, let’s continue building pathways that provide equal access to health for everyone . #HealthForAll #thalassemia #HepatitisCElimination #Teamwork #TransformingLives
